These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23534980)

  • 1. TNF-alpha and melphalan modulate a specific group of early expressed genes in a murine melanoma model.
    de Lima VC; de Carvalho AF; Morato-Marques M; Hashimoto VL; Spilborghs GM; Marques SM; Landman G; Torres C; Braga Ribeiro K; Brentani H; Reis LF; Dias AA
    Cytokine; 2013 May; 62(2):217-25. PubMed ID: 23534980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
    Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
    Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
    Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
    Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
    Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
    Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs].
    Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM
    Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
    Varghese S; Xu H; Bartlett D; Hughes M; Pingpank JF; Beresnev T; Alexander HR
    Ann Surg Oncol; 2010 Jul; 17(7):1870-7. PubMed ID: 20221901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study.
    Gutman M; Sofer D; Lev-Chelouche D; Merimsky O; Klausner JM
    Invasion Metastasis; 1997; 17(4):169-75. PubMed ID: 9778589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
    de Wilt JH; Manusama ER; van Etten B; van Tiel ST; Jorna AS; Seynhaeve AL; ten Hagen TL; Eggermont AM
    Br J Cancer; 2000 Nov; 83(9):1176-82. PubMed ID: 11027431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of recombinant human TNF in human cancer therapy.
    Lejeune FJ; Liénard D; Matter M; Rüegg C
    Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.
    Bonvalot S; de Baere T; Mendiboure J; Paci A; Farace F; Drouard-Troalen L; Bonnet L; Hakime A; Bonniaud G; Raynard B; Israel P; Le Cesne A; Eggermont AM; Laplanche A; Muret J
    Ann Surg; 2012 Feb; 255(2):281-6. PubMed ID: 22241290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
    Brunstein F; Hoving S; Seynhaeve AL; van Tiel ST; Guetens G; de Bruijn EA; Eggermont AM; ten Hagen TL
    J Natl Cancer Inst; 2004 Nov; 96(21):1603-10. PubMed ID: 15523089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between TNFalpha and tumor rejection induced by a single dose of melphalan in C57BL/6 mice].
    Li ML; Li CG; Shu XH; Jiang MN; Jia YJ; Qin ZH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Apr; 23(4):320-3. PubMed ID: 17428385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
    Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
    Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mouse model of isolated limb perfusion for extremity melanoma.
    Kim M; Camoriano M; Muhitch JB; Kane JM; Skitzki JJ
    J Surg Res; 2012 Nov; 178(1):294-8. PubMed ID: 22494912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.